Home » Stocks » KLDO

Kaleido Biosciences, Inc. (KLDO)

Stock Price: $12.62 USD 0.18 (1.45%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $12.35 -0.27 (-2.14%) Jan 27, 7:04 AM
Market Cap 454.09M
Revenue (ttm) 732,000
Net Income (ttm) -81.12M
Shares Out 35.55M
EPS (ttm) -2.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $12.62
Previous Close $12.44
Change ($) 0.18
Change (%) 1.45%
Day's Open 12.49
Day's Range 12.26 - 13.03
Day's Volume 73,214
52-Week Range 3.62 - 13.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Key...

GlobeNewsWire - 1 week ago

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P....

GlobeNewsWire - 3 weeks ago

Topline data for two studies of KB109 are expected in the first quarter of 2021 Topline data for two studies of KB109 are expected in the first quarter of 2021

24/7 Wall Street - 1 month ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, MGTA
GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat ...

GlobeNewsWire - 2 months ago

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 -

GlobeNewsWire - 3 months ago

Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 wh...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome t...

Seeking Alpha - 3 months ago

Why Kaleido Stock Is Taking Off, And Why It Can Go Higher

GlobeNewsWire - 3 months ago

Top-line safety, tolerability and activity results expected in mid-2021 Top-line safety, tolerability and activity results expected in mid-2021

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcomin...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic en...

GlobeNewsWire - 5 months ago

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 -

GlobeNewsWire - 6 months ago

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population -

24/7 Wall Street - 6 months ago

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, MGTA
GlobeNewsWire - 7 months ago

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome...

Seeking Alpha - 8 months ago

Kaleido Biosciences, Inc. (KLDO) CEO Alison Lawton on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 -

GlobeNewsWire - 8 months ago

- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -

GlobeNewsWire - 9 months ago

LEXINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microb...

Zacks Investment Research - 9 months ago

Is (KLDO) Outperforming Other Medical Stocks This Year?

The Motley Fool - 1 year ago

The Super Bowl of healthcare kicked off early for these companies.

Other stocks mentioned: AMRN, BMY, BX, CLVS, DERM, ISRG, JNJ, LLY, MDT, RHHBY, SNY, SRNE
GlobeNewsWire - 1 year ago

LEXINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbi...

About KLDO

Kaleido Biosciences, a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiom... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 2019
Stock Exchange
NASDAQ
Ticker Symbol
KLDO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 15.42, which is an increase of 22.19% from the latest price.

Price Target
$15.42
(22.19% upside)
Analyst Consensus: Buy